Management is driven by risk stratification and life expectancy. Most localized cancers are indolent, so options range from active surveillance through radical prostatectomy and radiation (± androgen deprivation), balancing cure against the morbidity of treatment.
Pre-Treatment Evaluation
- Metastatic staging — not for asymptomatic low/intermediate-risk disease; performed for high-risk disease (and considered for unfavorable-intermediate). Use cross-sectional imaging (CT or mpMRI, moderate sensitivity/high specificity for nodes) plus bone scan; PSMA-PET (Ga-68 PSMA-11 or 18F-DCFPyL) is FDA-approved for high-risk staging and outperforms conventional imaging (proPSMA: 27% greater accuracy), though the survival benefit of acting on molecular-imaging findings is unproven.
- Life expectancy — treatment generally requires a minimum 8–10-year life expectancy to reduce death risk; use validated calculators (clinician estimates are unreliable).
Risk stratification (2022 AUA — PSA, clinical stage, grade group):
| Risk | Criteria |
|---|---|
| Low | PSA <10 and Grade Group 1 and cT1–T2a |
| Intermediate | PSA 10–<20, or GG2–3, or cT2b–c. Favorable: <50% cores positive and (GG1 with 1 IR factor, or GG2 with no other IR factor). Unfavorable: GG3, or GG2 with ≥1 other IR factor or ≥50% cores, or GG1 with 2 IR factors |
| High | PSA ≥20, or GG4–5, or cT3 |
Older models include D'Amico (predicts biochemical recurrence), Epstein criteria (identify insignificant cancer for AS), and the Cambridge Prognostic Groups (cancer-specific survival). Intraductal/cribriform morphology and high PSA density worsen prognosis; tissue genomic tests (Prolaris, Oncotype DX, Decipher) are used selectively.
Treatment by Risk Stratum (2022 AUA)
| Situation | Recommended options |
|---|---|
| Life expectancy ≤5 years | Watchful waiting |
| Low-risk | Active surveillance preferred (select patients may elect definitive therapy) |
| Favorable intermediate-risk | Active surveillance, radical prostatectomy, or radiation without ADT |
| Unfavorable intermediate- or high-risk (LE >10 y) | Radical prostatectomy, or radiation + ADT (4–6 months for unfavorable intermediate; 18–36 months for high-risk) |
For sufficiently high-risk disease (node-positive, or ≥2 of: cT3, PSA ≥40, Gleason ≥8), radiation + ADT may add 2 years of abiraterone + prednisone.
Conservative Management
- Watchful waiting — palliative intent, no routine cancer surveillance; for asymptomatic men with limited life expectancy (AUA <5 years; NCCN <5–10). At 10 years, the risk of cancer-specific death is ~15% and metastasis ~20%. Intervene (with palliative ADT) for symptomatic progression, upper-tract obstruction, or metastasis.
- Active surveillance — defers definitive treatment while retaining curative potential; the preferred option for low-risk disease (and selected favorable-intermediate disease with low PSA density, low volume, and low % Gleason 4). It reduces overdiagnosis/overtreatment (cancer-specific mortality/metastasis <1% at 10 years) at the cost of repeat biopsies and a small risk of missing the window for cure. Selection uses the Epstein criteria. Disease reclassification (often initial misclassification rather than true progression) occurs in ~25–50% within 5 years; risk factors include African-American race, BRCA2 (9× risk), and high PSA density.
- Follow-up: PSA no more than every 6 months, DRE every 2 years, and surveillance biopsy every 1–4 years, with a confirmatory biopsy at 3–6 (or within 12) months; obtain mpMRI if the diagnostic biopsy lacked it (ASIST: MRI-targeted biopsy reduced later AS failures). Triggers for intervention: grade progression, increased cancer volume, rapidly rising PSA, or patient anxiety.
Observation vs treatment RCTs: PIVOT (Wilt) — no early survival difference, but an overall-survival benefit for radical prostatectomy emerged at 18.6 years (less so in low-risk/elderly men); SPCG-4 (Bill-Axelson) — prostatectomy improved overall, cancer-specific, and metastasis-free survival; ProtecT (Hamdy, 15 years) — no cancer-specific or overall survival difference between monitoring, surgery, and radiotherapy, but monitoring had more metastasis and ADT use.
Radical Prostatectomy
Offers possible cure with accurate pathologic staging and readily identified failure (allowing salvage radiation); disadvantages are recovery, possible incomplete resection, and morbidity (erectile dysfunction, incontinence). See the Radical Prostatectomy procedure page for surgical anatomy and operative technique.
- Approaches: open (perineal — less blood loss/shorter time but no access for lymphadenectomy and higher rectal-injury/fecal-incontinence risk; vs retropubic), laparoscopic, and robot-assisted (Coughlin 2018 RCT: no urinary/sexual difference vs open; minimally-invasive benefit). Generally offered up to ~76 years.
- Nerve-sparing — preserve neurovascular bundles when oncologically appropriate (lowers ED risk without increasing positive margins); questionable with extensive/high-grade disease, palpable EPE, PSA >10, or poor baseline erections.
- Pelvic lymphadenectomy — provides staging but no consistent survival benefit; if done, perform an extended dissection (obturator, external iliac, internal iliac); select by nomogram (NCCN thresholds 2–7%); complete the prostatectomy if positive nodes are found.
- Complications: incontinence (pads at 7–12 years ~18–24% vs ~3–8% radiotherapy), erectile dysfunction, vesicourethral anastomotic stenosis (1.3–4.8%; less with robotic; up to 22–40% after salvage RP), and (robotic) incisional hernia.
- Cancer control: PSA should be undetectable by ~2 months. Adverse features: non-organ-confined disease, lymphovascular invasion, EPE, positive margins, seminal-vesicle invasion, nodal metastasis. Nomograms: Partin tables (pathologic stage), Kattan (biochemical recurrence), CAPRA (age, PSA, stage, Gleason, % positive cores). Neoadjuvant ADT lowers positive margins but does not improve survival; neoadjuvant chemotherapy rarely gives complete responses.
Radiation Therapy
Pre-RT prognostic factors: PSA/velocity, grade group, % positive cores, cT stage, MRI. Contraindications — ST-LIAR: prostate Size >60 cc (brachytherapy) and prior TURP (brachytherapy) — relative; significant LUTS, IBD, Ataxia telangiectasia (absolute — severe radiation response), and prior pelvic Radiation.
- Modalities: EBRT has advanced from 3DCRT → IMRT (less rectal/bladder dose) → IGRT → SBRT/CyberKnife (hypofractionation). Dose escalation is standard (76–80+ Gy; ~70–72 low-risk, 75–76 intermediate, ≥80 high-risk). Brachytherapy delivers higher prostate doses (LDR: ~145 Gy iodine-125, ~125 Gy palladium-103; or temporary HDR), with rectal toxicity the limiting factor.
- EBRT + ADT: short-term (~6 months) for intermediate-risk; long-term (18–36 months) for high-risk. Supporting trials: EORTC 22863 (Bolla — long-term ADT improved OS), RTOG 86-10 and 92-02 (longer ADT benefit), EORTC 22961 (3 years > 6 months), and PR3/PR07 + SPCG-7 (adding radiation to ADT improves survival in locally advanced disease). PACE-B: SBRT non-inferior to conventional radiotherapy for low/intermediate-risk disease.
- Toxicity: GU (more with brachytherapy; acute urinary retention 12–35% after brachytherapy), GI (more with EBRT; 5–10% chronic proctitis), erectile dysfunction (~50%, more with EBRT than brachytherapy), and secondary malignancy (~1/70 living >10 years).
- PSA after RT: the nadir is reached over 2–3 years (not undetectable — residual benign epithelium persists). Failure definitions: ASTRO (3 consecutive rises) and the Phoenix definition (nadir + 2 ng/mL, not backdated). A PSA bounce (a transient rise of ~0.1–0.5 ng/mL above nadir, then decline) occurs in ~20%, more often after brachytherapy, usually within 2 years. Post-RT biopsy (to assess local control) is best at 30–36 months.
RP vs radiotherapy: no randomized comparison; surgery tends to fail at the margins and radiotherapy in the tumor center.
Other Treatments
- ADT monotherapy is never curative and is reserved for palliation in high-risk patients with local symptoms and limited life expectancy (the bicalutamide Early Prostate Cancer Programme showed benefit in locally advanced but not localized disease).
- Whole-gland or focal ablation — per AUA, considered only in selected, informed intermediate-risk patients (prioritize trials); not for low-risk (use AS) or high-risk (insufficient data). The index-lesion hypothesis underpins focal therapy (the largest focus drives behavior). Modalities: cryoablation, HIFU (AUR ~20%; prostate ≤40 mL), focal laser, irreversible electroporation, and photodynamic therapy; follow-up uses PSA, MRI, and targeted ± systematic biopsy.
High-Risk and Follow-Up
About 15% of localized disease is high-risk; options are radical prostatectomy or radiation + ADT (and clinical trials), with neoadjuvant/adjuvant intensification under study (PROTEUS, ATLAS, ENZARAD). Follow-up after treatment (2022 AUA): provide an individualized recurrence estimate; PSA every 3–6 months for 2 years, every 6 months through year 5, then annually, with validated QoL instruments for urinary/bowel/sexual function.
Self-Test
1. 10-year risk of cancer death and metastasis on watchful waiting? ~15% cancer-specific death and ~20% metastasis.
2. Who should be considered for watchful waiting? Men without high-risk disease and limited life expectancy — preferred at <5 years, an option at <10 years.
3. Indications for intervention on active surveillance? Grade progression, increased cancer volume on repeat biopsy, rapidly rising PSA, and patient anxiety.
4. Contraindications to radical radiotherapy (ST-LIAR)? Size >60 g (brachytherapy), prior TURP (brachytherapy), significant LUTS, IBD, ataxia telangiectasia, and prior pelvic radiation.
5. Advantages/disadvantages of perineal vs retropubic prostatectomy? Perineal — less blood loss and shorter operating time, but no access for lymphadenectomy and higher rectal-injury risk.
6. Definitions of biochemical failure after radiotherapy? ASTRO — 3 consecutive PSA rises (backdated to midway between nadir and first rise); Phoenix — nadir + 2 ng/mL (not backdated).
7. PSA bounce — definition and which modality? A rise of ~0.1–0.5 ng/mL above nadir followed by a decline; more common after brachytherapy.
8. Optimal timing of post-radiation biopsy? 30–36 months.
9. Radiotherapy toxicity profile — EBRT vs brachytherapy? GI toxicity and erectile dysfunction are more common with EBRT; GU toxicity is more common with brachytherapy; both carry a small secondary-malignancy risk.